Journal
CANCER RESEARCH
Volume 81, Issue 7, Pages 1883-1895Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-20-1540
Keywords
-
Categories
Funding
- NIH [CA188252]
- Department of Defense Breast Cancer Research Program [W81XWH-11-10430]
- University of Michigan Forbes Institute for Cancer Discovery
- L.K. Whittier Foundation
Ask authors/readers for more resources
GRP78 is a key regulator of ER stress signaling, and YUM70, a novel inhibitor targeting GRP78, induces ER stress-mediated apoptosis in pancreatic cancer cells with in vivo efficacy and synergistic cytotoxicity when combined with topoisomerase and HDAC inhibitors.
GRP78 (glucose-regulated protein, 78 kDa) is a key regulator of endoplasmic reticulum (ER) stress signaling. Cancer cells are highly proliferative and have high demand for protein synthesis and folding, which results in significant stress on the ER. To respond to ER stress and maintain cellular homeostasis, cells activate the unfolded protein response (UPR) that promotes either survival or apoptotic death. Cancer cells utilize the UPR to promote survival and growth. In this study, we describe the discovery of a series of novel hydroxyquinoline GRP78 inhibitors. A representative analogue, YUM70, inhibited pancreatic cancer cell growth in vitro and showed in vivo efficacy in a pancreatic cancer xenograft model with no toxicity to normal tissues. YUM70 directly bound GRP78 and inactivated its function, resulting in ER stress-mediated apoptosis. A YUM70 analogue conjugated with BODIPY showed colocalization of the compound with GRP78 in the ER. Moreover, a YUM70-PROTAC (proteolysis targeting chimera) was synthesized to force degradation of GRP78 in pancreatic cancer cells. YUM70 showed a strong synergistic cytotoxicity with topotecan and vorinostat. Together, our study demonstrates that YUM70 is a novel inducer of ER stress, with predinical efficacy as a monotherapy or in combination with topoisomerase and HDAC inhibitors in pancreatic cancer. Significance: This study identifies a novel ER stress inducer that binds GRP78 and inhibits pancreatic cancer cell growth in vitro and in vivo, demonstrating its potential as a therapeutic agent for pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available